4 research outputs found

    Subgroup analyses of mesenchymal stem cellson the odds of mortality in preclinical models of acute lung injury.

    No full text
    <p><b>Fig 3A</b>: Forest plot of mesenchymal stem cells on the odds of mortality at a priori determined time points. <b>Fig 3B</b>: Forest plot of mesenchymal stem cells on the odds of mortality according to animal species, gender and experimental model of acute lung injury. <b>Fig 3C</b>: Forest plot of mesenchymal stem cells on the odds of mortality according to MSC origin, source, preparation, and route of administration, as well as comparator control groups. Subgroup analyses conducted to examine the robustness of the treatment effect according to the clinical relevance of the ALI model (timing of MSC administration in relation to ALI induction and resuscitation of the animals) (<b>Fig 3D</b>) indicated a reduction in the odds of death regardless of the timing of administration of the cells, although the protective effect of MSCs appeared less the longer the delay in treatment initiation. There were no significant differences in the treatment effect of MSCs with more clinically relevant animal models (e.g. use of antibiotics, resuscitation fluid, or the combination of resuscitation fluid and antibiotics). Analyses conducted according to selective outcome reporting and incomplete outcome reporting did not reveal substantial differences in the estimate of effect (<b>Fig 3E</b>). <b>Fig 3D</b>: Forest plot of mesenchymal stem cells on the odds of mortality according to timing of MSC administration and method of resuscitation. <b>Fig 3E</b>: Forest plot of mesenchymal stem cells on the odds of mortality according to domains of the Cochrane Risk of Bias.</p
    corecore